(TXN - Get Report)
downgraded at Pacific Crest. Estimates also cut, given an expected inventory correction.
STOCK COMMENTS / EPS CHANGES
(CELG - Get Report)
target raised at Jefferies to $91, Jefferies said. Positive topline data for Abraxane. Buy rating.
target raised at Oppenheimer to $80, Oppenheimer said. Bullish following management meetings. Outperform rating.
cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 41% since June. $11 price target.
estimates, target reduced at BMO. Shares of EXPR now seen reaching $15, according to BMO Capital. Estimates also cut, given the company's new guidance. Outperform rating.
numbers lowered at Jefferies. Shares of HAL now seen reaching $44, Jefferies said. Estimates also lowered on North America weakness. Buy rating.
Helmerich & Payne
numbers lowered at Jefferies. Shares of HP now seen reaching $55, Jefferies said. Estimates also lowered on North American weakness. Buy rating.
numbers raised at Citigroup. Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
numbers cut at Citigroup. Shares of MOS now seen reaching $69, Citigroup said. Estimates also lowered on disappointing quarterly results. Buy rating.
estimates, target reduced at Credit Suisse. MSCI estimates were cut through 2014, Credit Suisse said. Vanguard loss will cut into profits. Outperform rating and new $31 price target.
estimates trimmed at UBS through 2012 on higher iPhone sales, UBS said. Neutral rating and $35 price target.
estimates, target increased at ThinkEquity. Z estimates were raised through 2013, ThinkEquity said. Strong agent demand will improve pricing power. Buy rating and new $49 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on